**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
G. Patrick Meier et al.

Serial No.: 10/575,188

Filed: April 7, 2006

For: SITE AND RATE SELECTIVE PRODRUG FORMULATIONS OF D609 WITH ANTIOXIDANT AND ANTICANCER ACTIVITY

Group Art Unit: 1626

Examiner: Unknown

Atty. Dkt. No.: MESC:009US

Confirmation No.: 7144

CERTIFICATE OF ELECTRONIC TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

February 13, 2007
Date

Michael R. Krawzsenek

## INFORMATION DISCLOSURE STATEMENT

**MS AMENDMENT**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/MESC:009US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 13, 2007

| Form PTO-1449 (modified) | Atty. Docket No. MESC:009US | Serial No. 10/575,188 |
|---|---|---|
| **List of Patents and Publications for Applicant's** INFORMATION DISCLOSURE STATEMENT | **Applicant:** G. Patrick Meier *et al.* | |
| (Use several sheets if necessary) | **Filing Date:** April 7, 2006 | **Group:** 1626 |

| U.S. Patent Documents | Foreign Patent Documents | Other Art |
|---|---|---|
| *See Page 1* | *See Page 1* | *See Page 1-4* |

## U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|---|---|---|---|---|---|---|---|
| | | | | | | | |

## Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Language |
|---|---|---|---|---|---|
| | | | | | |

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|---|---|---|
| | C1 | Amtmann and Sauer, "Selective killing of tumor cells by xanthates," *Cancer Lett.*, 35:237-244, 1987. |
| | C2 | Amtmann and Sauer, "Tumor necrosis factor induces necrosis of human carcinoma xenografts in the presence of tricyclodecan-9-yl-xanthogenate and lauric acid," *Int. J. Cancer*, 45:1113-1118, 1990. |
| | C3 | Amtmann, "The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C," *Drugs Exp. Clin. Res.*, 22:287-294, 1996. |
| | C4 | Bai *et al.*, "Prodrug Modification Increases Potassium Tricyclo[5,2.1.0]-decan-8-yl Dithiocarbonate (D609) Chemical Stability and Cytotoxicity Against U937 Leukemia Cells," *J. of Pharmaceutical and Experimental Therapeutics*, 309:1051-1059, 2004. |
| | C5 | Bettaieb *et al.*, "Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis," *Mol. Pharmacol.*, 55:118-125, 1999. |
| | C6 | Capizzi, "The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine," *Semin. Oncol.*, 26:3-21, 1999. |
| | C7 | Chevion *et al.*, "Evaluation of plasma low molecular weight antioxidant capacity by cyclic voltammetry," *Free Radic. Biol. Med.*, 22:411-421, 1997. |

25714478.1

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| Form PTO-1449 (modified) | Atty. Docket No. MESC:009US | Serial No. 10/575,188 |
|---|---|---|
| List of Patents and Publications for Applicant's<br>INFORMATION DISCLOSURE STATEMENT | Applicant: G. Patrick Meier *et al.* | |
| (Use several sheets if necessary) | Filing Date: April 7, 2006 | Group: 1626 |

| U.S. Patent Documents | Foreign Patent Documents | Other Art |
|---|---|---|
| *See Page 1* | *See Page 1* | *See Page 1-4* |

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|---|---|---|
| | C8 | Culy and Spencer, "Amifostine: An Update on its Clinical Status as a Cytoprotectant in Patients with Cancer Receiving Chemotherapy or Radiotherapy and its Potential Therapeutic Application in Myelodysplastic Syndrome," *Drugs*, 61:641-684, 2001. |
| | C9 | Druker and Lydon, "Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia," *J. Clin. Invest.*, 105:3-7, 2000. |
| | C10 | Furstenberger *et al.*, "Tumor prevention by a xanthate compound in experimental mouse-skin tumorigenesis," *Int. J. Cancer*, 43:508-512, 1989. |
| | C11 | Gazdar and Minna, "Targeted therapies for killing tumor cells," *Proc. Natl. Acad. Sci. USA*, 98:10028-10030, 2001. |
| | C12 | Gibbs, "Mechanism-Based Target Identification and Drug Discovery in Cancer Research," *Science*, 287:1969-1973, 2000. |
| | C13 | Giron-Calle *et al.*, "Priming of alveolar macrophage respiratory burst by H(2)O(2) is prevented by phosphatidylcholine-specific phospholipase C inhibitor Tricyclodecan-9-yl-xanthate (D609)," *J. Pharmacol. Exp. Ther.*, 301:87-94, 2002. |
| | C14 | Greenberger *et al.*, "Modulation of redox signal transduction pathways in the treatment of cancer," *Antioxid. Redox. Signal*, 3:347-359, 2001. |
| | C15 | Hospers *et al.*, "The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects," *Br. J. Cancer*, 80:629-638, 1999. |
| | C16 | Krise *et al.*, "A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs," *J. Pharm. Sci.*, 88:922-927, 1999. |
| | C17 | Krise *et al.*, "A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs," *J. Pharm. Sci.*, 88:928-932, 1999. |
| | C18 | Luberto and Hannun, "Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C?," *J. Biol. Chem.*, 273:14550-14559, 1998. |

25714478.1

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| Form PTO-1449 (modified) | Atty. Docket No. MESC:009US | Serial No. 10/575,188 |
|---|---|---|
| **List of Patents and Publications for Applicant's** INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | **Applicant:** G. Patriek Meier *et al.* | |
| | **Filing Date:** April 7, 2006 | **Group:** 1626 |

| U.S. Patent Documents | Foreign Patent Documents | Other Art |
|---|---|---|
| *See Page 1* | *See Page 1* | *See Page 1-4* |

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|---|---|---|
| | C19 | Luberto *et al.*, "Differential effects of sphingomyelin hydrolysis and resynthesis on the activation of NF-kappa B in normal and SV40-transformed human fibroblasts," *J. Biol. Chem.*, 275:I4760-I4766, 2000. |
| | C20 | Machleidt *et al.*, "Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C," *J. Exp. Med.*, 184:725-733, 1996. |
| | C21 | Meng *et al.*, "Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells," *Exp. Cell Res.*, 292:385-392, 2004. |
| | C22 | Nudelman *et al.*, "Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases," *Eur. J. Med. Chem.*, 36:63-74, 2001. |
| | C23 | Paris *et al.*, "Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice," *Science*, 293:293-297, 2001. |
| | C24 | PCT International Search Report, May I3, 2005. |
| | C25 | Perry and Ridgway, "The role of de novo ceramide synthesis in the mechanism of action of the tricyclic xanthate D609," *J. Lipid Res.*, 45:164-173, 2004. |
| | C26 | Poggi *et al.*, "Sensitizers and protectors of radiation and chemotherapy," *Curr. Probl. Cancer*, 25:334-411, 2001. |
| | C27 | Porn-Ares *et al.*, "Induction of apoptosis and potentiation of TNF- and Fas-mediated apoptosis in U937 cells by the xanthogenate compound D609," *Exp. Cell Res.*, 235:48-54, 1997. |
| | C28 | Rao, *Xanthates and Related Compounds*, Marcel Dekker, Inc., NY, I97I. |
| | C29 | Riboni *et al.*, "Basic fibroblast growth factor-induced proliferation of primary astrocytes. evidence for the involvement of sphingomyelin biosynthesis," *J. Biol. Chem.*, 276:12797-12804, 2001. |
| | C30 | Santana *et al.*, "Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis," *Cell*, 86:189-199, 1996. |
| | C31 | Sauer *et al.*, "Systemic treatment of a human epidermoid non-small cell lung carcinoma xenograft with a xanthate compound causes extensive intratumoral necrosis," *Cancer Lett.*, 53:97-102, 1990. |

25714478.1

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| Form PTO-1449 (modified) | Atty. Docket No. MESC:009US | Serial No. 10/575,188 |
|---|---|---|
| List of Patents and Publications for Applicant's<br>INFORMATION DISCLOSURE STATEMENT | Applicant: G. Patriek Meier *et al.* | |
| (Use several sheets if necessary) | Filing Date: April 7, 2006 | Group: 1626 |

| U.S. Patent Documents | Foreign Patent Documents | Other Art |
|---|---|---|
| *See Page 1* | *See Page 1* | *See Page 1-4* |

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|---|---|---|
| | C32 | Schick *et al.*, "Antitumoral activity of a xanthate compound. I. Cytotoxicity studies with neoplastic cell lines in vitrom" *Cancer Lett.*, 46:143-147, 1989. |
| | C33 | Schick *et al.*, "Antitumoral activity of a xanthate compound. II. Therapeutic studies in murine leukemia and tumor models in vivo," *Cancer Lett.*, 46:149-152, 1989. |
| | C34 | Schutze *et al.*, "TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown," *Cell*, 71:765-776, 1992. |
| | C35 | Schutze *et al.*, "Tumor necrosis factor induces rapid production of 1'2'diacylglycerol by a phosphatidylcholine-specific phospholipase C," *J. Exp. Med.*, 174:975-988, 1991. |
| | C36 | Smith and Clark, In: *Drug latentiation and prodrugs*, Delgado and Remers (Eds.), Lippincott-Raven Publishers, Philadelphia, 123-138, 1998. |
| | C37 | Spencer and Goa, "Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector," *Drugs*, 50:1001-1031, 1995. |
| | C38 | Zhou *et al.*, "D609 inhibits ionizing radiation-induced oxidative damage by acting as a potent antioxidant," *J. Pharmacol. Exp. Ther.*, 298:103-109, 2001. |
| | C39 | Zhou *et al.*, "Effects of NF-kappaB1 (p50) targeted gene disruption on ionizing radiation-induced NF-kappaB activation and TNFalpha, IL-1alpha, IL-1beta and IL-6 mRNA expression in vivo," *Int. J. Radiat. Biol.*, 77:763-772, 2001. |

25714478.1

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.